New Zealand markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.30-0.43 (-7.50%)
At close: 04:00PM EST
5.37 +0.07 (+1.32%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.73
Open5.55
Bid5.35 x 2200
Ask5.45 x 1000
Day's range5.04 - 5.72
52-week range4.32 - 10.87
Volume1,792,230
Avg. volume6,158,603
Market cap58.087M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-4.71
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results

    Entered into $31.25 million Private Placement Agreement Completed Initial Public Offering of Common Stock and Raised $28.75 million in Gross Proceeds Dosed First Patient in Phase 2 ER+, PR+, HER2- Metastatic Breast Cancer Clinical Trial PHILADELPHIA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced financial results f

  • GlobeNewswire

    Context Therapeutics Inc. Announces $31.25 Million Private Placement

    PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced that it has entered into definitive securities purchase agreements for a private placement with accredited investors of 5,000,000 shares of common stock of Context Therapeutics together with warrants to purchase 5,

  • GlobeNewswire

    Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

    Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancerPHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented